Monday, May 28, 2018
 
 
Company News: Page (1) of 1 - 01/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Supernus Mourns the Loss of Board Member William Nuerge

(January 12, 2018)

ROCKVILLE, Md., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), It is with great sadness that Supernus announces that William Nuerge, a valued member of its Board of Directors, passed away on January 10, 2018. Mr. Nuerge had a long and distinguished career in the pharmaceutical industry, including serving as CEO of Shire US and Xanodyne Pharmaceuticals until his retirement. Mr. Nuerge joined the Supernus Board of Directors in 2006.

"We are deeply saddened by the passing of Bill, a colleague and a long-time friend who will be sorely missed," said Jack Khattar, President and CEO, Supernus. "For eleven years, Bill contributed greatly to Supernus through his broad business expertise and deep knowledge of operational performance. Bill's death is a tragedy for his family and a great loss to our company. I greatly appreciated his wisdom and counsel on company matters. Our thoughts and prayers are with his family and friends."

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XRŪ (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XRŪ (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.

Contact:

Jack A. Khattar, President and CEOGregory S. Patrick, Vice President and CFO


Supernus Pharmaceuticals, Inc.
301-838-2591

Or

Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.[email protected]


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Global Chromatography Reagents Market Analysis, Growth, Trends & Forecast 2018-2023, With The Market Forecasted to Register a CAGR of More Than 7% - ResearchAndMarkets.com
  • Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023

    Cancer
  • Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Bavarian Nordic Announces Interim Results for the First Three Months of 2018
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines